gracell biotechnologies inc. is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. leveraging its pioneering fastcar and truucar technology platforms, gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional car-t therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective car-t therapies for solid tumors.
Company profile
Ticker
GRCL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GRCL stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
4 Mar 24
EFFECT
Notice of effectiveness
28 Feb 24
EFFECT
Notice of effectiveness
28 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Feb 24
POS AM
Prospectus update (post-effective amendment)
26 Feb 24
POS AM
Prospectus update (post-effective amendment)
26 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Feb 24
25-NSE
Exchange delisting
22 Feb 24
6-K
Gracell Biotechnologies Acquisition Completed
22 Feb 24
6-K
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
20 Feb 24
Transcripts
GRCL
Earnings call transcript
2023 Q3
13 Nov 23
GRCL
Earnings call transcript
2023 Q2
14 Aug 23
GRCL
Earnings call transcript
2023 Q1
15 May 23
GRCL
Earnings call transcript
2022 Q4
13 Mar 23
GRCL
Earnings call transcript
2022 Q3
14 Nov 22
GRCL
Earnings call transcript
2022 Q2
15 Aug 22
GRCL
Earnings call transcript
2022 Q1
16 May 22
GRCL
Earnings call transcript
2021 Q4
14 Mar 22
GRCL
Earnings call transcript
2021 Q2
17 Aug 21
GRCL
Earnings call transcript
2020 Q4
10 Mar 21
Latest ownership filings
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
William Cao Wei
14 Feb 24
SC 13G
Sio Capital Management, LLC
14 Feb 24
SC 13G/A
LAV Biosciences Fund V, L.P.
13 Feb 24
SC 13G/A
Vivo Opportunity Fund Holdings, L.P.
13 Feb 24
144
Notice of proposed sale of securities
21 Nov 23
SC 13G/A
Temasek Holdings (Private) Ltd
19 Oct 23
144
Notice of proposed sale of securities
12 Oct 23
144
Notice of proposed sale of securities
23 Aug 23
SC 13G
RA CAPITAL MANAGEMENT, L.P.
21 Aug 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 42 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 143.07 mm |
Total shares | 128.38 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
William Cao Wei | 75.25 mm | $0.00 |
Vivo Opportunity Fund | 38.15 mm | $143.07 mm |
LAV Biosciences Fund V | 14.98 mm | $0.00 |